5/9/2007

An FDA staff report raised concerns about risks to cancer patients from anemia drugs such as Amgen's Aranesp and Johnson & Johnson's Procrit. The FDA cited results from five trials showing decreased survival times for patients receiving the drugs, compared with patients getting blood transfusions. An advisory panel is scheduled to meet Thursday to consider stricter labeling for the drugs.

Related Summaries